Coronary stents: looking forward.

[1]  P. Serruys,et al.  Final results of the HEALING IIB trial to evaluate a bio-engineered CD34 antibody coated stent (Genous™Stent) designed to promote vascular healing by capture of circulating endothelial progenitor cells in CAD patients. , 2011, Atherosclerosis.

[2]  Peter Jüni,et al.  Comparison of titanium-nitride-oxide-coated stents with zotarolimus-eluting stents for coronary revascularization a randomized controlled trial. , 2011, JACC. Cardiovascular interventions.

[3]  T. Vahlberg,et al.  Long-term clinical outcome with titanium-nitride-oxide-coated stents and paclitaxel-eluting stents for coronary revascularization in an unselected population. , 2010, International journal of cardiology.

[4]  P. Serruys,et al.  Three-year results of clinical follow-up after a bioresorbable everolimus-eluting scaffold in patients with de novo coronary artery disease: the ABSORB trial. , 2010, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.

[5]  B. Cortese,et al.  Paclitaxel-coated balloon versus drug-eluting stent during PCI of small coronary vessels, a prospective randomised clinical trial. The PICCOLETO Study , 2010, Heart.

[6]  Hiram G Bezerra,et al.  Strut Coverage and Vessel Wall Response to a New-Generation Paclitaxel-Eluting Stent With an Ultrathin Biodegradable Abluminal Polymer: Optical Coherence Tomography Drug-Eluting Stent Investigation (OCTDESI) , 2010, Circulation. Cardiovascular interventions.

[7]  Volker Klauss,et al.  Comparison of zotarolimus-eluting and everolimus-eluting coronary stents. , 2010, The New England journal of medicine.

[8]  A. Silman,et al.  Identification of late-onset hypogonadism in middle-aged and elderly men. , 2010, The New England journal of medicine.

[9]  A. Kastrati,et al.  2-year clinical and angiographic outcomes from a randomized trial of polymer-free dual drug-eluting stents versus polymer-based Cypher and Endeavor [corrected] drug-eluting stents. , 2010, Journal of the American College of Cardiology.

[10]  Krzysztof Milewski,et al.  Development of a Novel Prohealing Stent Designed to Deliver Sirolimus From a Biodegradable Abluminal Matrix , 2010, Circulation. Cardiovascular interventions.

[11]  P. Fitzgerald,et al.  A randomised comparison of novolimus-eluting and zotarolimus-eluting coronary stents: 9-month follow-up results of the EXCELLA II study. , 2010 .

[12]  F. Eberli,et al.  The twelve-month outcomes of a biolimus eluting stent with a biodegradable polymer compared with a sirolimus eluting stent with a durable polymer. , 2010, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.

[13]  P. Serruys,et al.  IVUS radiofrequency analysis in the evaluation of the polymeric struts of the bioabsorbable everolimus‐eluting device during the bioabsorption process , 2010, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.

[14]  J. Ormiston,et al.  First human use of the TAXUS Petal paclitaxel-eluting bifurcation stent. , 2010 .

[15]  Patrick W Serruys,et al.  Endothelial progenitor cell capture stents: will this technology find its niche in contemporary practice? , 2010, European heart journal.

[16]  Georg Nickenig,et al.  A novel paclitaxel-eluting stent with an ultrathin abluminal biodegradable polymer 9-month outcomes with the JACTAX HD stent. , 2010, JACC. Cardiovascular interventions.

[17]  Saibal Kar,et al.  Polymer-Free Biolimus A9–Coated Stent Demonstrates More Sustained Intimal Inhibition, Improved Healing, and Reduced Inflammation Compared With a Polymer-Coated Sirolimus-Eluting Cypher Stent in a Porcine Model , 2010, Circulation. Cardiovascular interventions.

[18]  Yoshinobu Onuma,et al.  In vivo evaluation of stent strut distribution patterns in the bioabsorbable everolimus-eluting device: An OCT ad hoc analysis of the revision 1.0 and revision 1.1 stent design in the ABSORB clinical trial , 2010 .

[19]  A. Baumbach,et al.  Randomized Trial of Simple Versus Complex Drug-Eluting Stenting for Bifurcation Lesions: The British Bifurcation Coronary Study: Old, New, and Evolving Strategies , 2010, Circulation.

[20]  P. Serruys,et al.  Benefits of and safety concerns associated with drug-eluting coronary stents , 2010, Expert review of cardiovascular therapy.

[21]  R. Whitbourn,et al.  Serial angiography and intravascular ultrasound: results of the SISC Registry (Stents In Small Coronaries). , 2010, JACC. Cardiovascular interventions.

[22]  John Yan,et al.  Elixir Medical's bioresorbable drug eluting stent (BDES) programme: an overview. , 2009, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.

[23]  A. Lafont,et al.  A.R.T.: concept of a bioresorbable stent without drug elution. , 2009, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.

[24]  M. Pollman.  Engineering a bioresorbable stent: REVA programme update. , 2009, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.

[25]  R. Pakala,et al.  Coating bioabsorption and chronic bare metal scaffolding versus fully bioabsorbable stent. , 2009, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.

[26]  P. Serruys,et al.  Ten-year follow-up of the IGAKI-TAMAI stent. A posthumous tribute to the scientific work of Dr. Hideo Tamai. , 2009, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.

[27]  R. Waksman.  Current state of the absorbable metallic (magnesium) stent. , 2009, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.

[28]  R. Schwartz,et al.  OrbusNeich fully absorbable coronary stent platform incorporating dual partitioned coatings. , 2009, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.

[29]  Jan Baan,et al.  Genous™ endothelial progenitor cell capturing stent vs. the Taxus Liberté stent in patients with de novo coronary lesions with a high-risk of coronary restenosis: a randomized, single-centre, pilot study , 2009, European heart journal.

[30]  M. Leon,et al.  Serial intravascular ultrasound analysis of bifurcation lesions treated using the novel self-expanding sideguard side branch stent. , 2009, The American journal of cardiology.

[31]  R. Whitbourn,et al.  Clinical and angiographic results with the next-generation resolute stent system: a prospective, multicenter, first-in-human trial. , 2009, JACC. Cardiovascular interventions.

[32]  John P A Ioannidis,et al.  Double Versus Single Stenting for Coronary Bifurcation Lesions: A Meta-Analysis , 2009, Circulation. Cardiovascular interventions.

[33]  G. Dangas,et al.  Bifurcation stenting with drug-eluting stents: a systematic review and meta-analysis of randomised trials. , 2009, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.

[34]  P. Serruys,et al.  Two-year clinical, angiographic, and intravascular ultrasound follow-up of the XIENCE V everolimus-eluting stent in the treatment of patients with de novo native coronary artery lesions: the SPIRIT II trial. , 2009, Circulation. Cardiovascular interventions.

[35]  M. Gawaz,et al.  Catheter-based delivery of fluid paclitaxel for prevention of restenosis in native coronary artery lesions after stent implantation. , 2009, Circulation. Cardiovascular interventions.

[36]  J. Ge,et al.  Simple versus complex stenting strategy for coronary artery bifurcation lesions in the drug-eluting stent era: a meta-analysis of randomised trials , 2009, Heart.

[37]  R. Virmani,et al.  Comparison of Inflammatory Response After Implantation of Sirolimus- and Paclitaxel-Eluting Stents in Porcine Coronary Arteries , 2009, Circulation.

[38]  J. Mehilli,et al.  Randomised trial of three rapamycin-eluting stents with different coating strategies for the reduction of coronary restenosis: 2-year follow-up results , 2009, Heart.

[39]  Ralf Degenhardt,et al.  Paclitaxel-Coated Balloon Catheter Versus Paclitaxel-Coated Stent for the Treatment of Coronary In-Stent Restenosis , 2009, Circulation.

[40]  John A Ormiston,et al.  Bioabsorbable coronary stents. , 2009, Circulation. Cardiovascular interventions.

[41]  P. Serruys,et al.  Randomized Comparison of the Nobori Biolimus A9-Eluting Coronary Stent With the Taxus Liberté Paclitaxel-Eluting Coronary Stent in Patients With Stenosis in Native Coronary Arteries: The NOBORI 1 Trial—Phase 2 , 2009, Circulation. Cardiovascular interventions.

[42]  F. Prati,et al.  Optical coherence tomographic results at six-month follow-up evaluation of the CATANIA coronary stent system with nanothin Polyzene-F surface modification (from the Assessment of The LAtest Non-Thrombogenic Angioplasty Stent [ATLANTA] trial). , 2009, The American journal of cardiology.

[43]  P. Serruys,et al.  First case of stenting of a vulnerable plaque in the SECRITT I trial—the dawn of a new era? , 2009, Nature Reviews Cardiology.

[44]  Galo Maldonado,et al.  1-year results of the hydroxyapatite polymer-free sirolimus-eluting stent for the treatment of single de novo coronary lesions: the VESTASYNC I trial. , 2009, JACC. Cardiovascular interventions.

[45]  C. von Birgelen,et al.  Coating irregularities of durable polymer-based drug-eluting stents as assessed by scanning electron microscopy. , 2009, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.

[46]  P. Vincent,et al.  A randomized optical coherence tomography study of coronary stent strut coverage and luminal protrusion with rapamycin-eluting stents. , 2009, JACC. Cardiovascular interventions.

[47]  A. Kastrati,et al.  Durability of antirestenotic efficacy in drug-eluting stents with and without permanent polymer. , 2009, JACC. Cardiovascular interventions.

[48]  P. Serruys,et al.  Lowering the dose of sirolimus, released from a nonpolymeric hydroxyapatite coated coronary stent, reduces signs of delayed healing. , 2009, JACC. Cardiovascular interventions.

[49]  Yi Li,et al.  Safety and efficacy of biodegradable polymer-coated sirolimus-eluting stents in "real-world" practice: 18-month clinical and 9-month angiographic outcomes. , 2009, JACC. Cardiovascular interventions.

[50]  Raimund Erbel,et al.  Early- and long-term intravascular ultrasound and angiographic findings after bioabsorbable magnesium stent implantation in human coronary arteries. , 2009, JACC. Cardiovascular interventions.

[51]  P. Fitzgerald,et al.  9-month clinical, angiographic, and intravascular ultrasound results of a prospective evaluation of the Axxess self-expanding biolimus A9-eluting stent in coronary bifurcation lesions: the DIVERGE (Drug-Eluting Stent Intervention for Treating Side Branches Effectively) study. , 2009, Journal of the American College of Cardiology.

[52]  Patrick W Serruys,et al.  A bioabsorbable everolimus-eluting coronary stent system (ABSORB): 2-year outcomes and results from multiple imaging methods , 2009, The Lancet.

[53]  F. Prati,et al.  First-in-man 1-year clinical outcomes of the Catania Coronary Stent System with Nanothin Polyzene-F in de novo native coronary artery lesions: the ATLANTA (Assessment of The LAtest Non-Thrombogenic Angioplasty stent) trial. , 2009, JACC. Cardiovascular interventions.

[54]  P. Serruys,et al.  First-in-man (FIM) study of the Stentys bifurcation stent--30 days results. , 2009, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.

[55]  G. Stone,et al.  Randomized Comparison of Everolimus-Eluting and Paclitaxel-Eluting Stents: Two-Year Clinical Follow-Up From the Clinical Evaluation of the Xience V Everolimus Eluting Coronary Stent System in the Treatment of Patients With De Novo Native Coronary Artery Lesions (SPIRIT) III Trial , 2009, Circulation.

[56]  M. Niemelä,et al.  Randomized Comparison of Coronary Bifurcation Stenting With the Crush Versus the Culotte Technique Using Sirolimus Eluting Stents: The Nordic Stent Technique Study , 2009, Circulation. Cardiovascular interventions.

[57]  Antonio Colombo,et al.  Randomized Study of the Crush Technique Versus Provisional Side-Branch Stenting in True Coronary Bifurcations: The CACTUS (Coronary Bifurcations: Application of the Crushing Technique Using Sirolimus-Eluting Stents) Study , 2009, Circulation.

[58]  M. Niemelä,et al.  Two-year follow-up after percutaneous coronary intervention with titanium-nitride-oxide-coated stents versus paclitaxel-eluting stents in acute myocardial infarction , 2009, Annals of medicine.

[59]  O. Muller,et al.  Interference of Drug-Eluting Stents With Endothelium-Dependent Coronary Vasomotion: Evidence for Device-Specific Responses , 2008, Circulation. Cardiovascular interventions.

[60]  P. Serruys,et al.  Abstract 5998: Final Results of the HEALING 2B Trial to Evaluate a Bioengineered CD34 Antibody Coated Stent (GenousTMStent) Designed to Promote Vascular Healing by Capture of Circulating Endothelial Progenitor Cells in CAD Patients , 2008 .

[61]  F. Eberli,et al.  Biolimus-eluting stent with biodegradable polymer versus sirolimus-eluting stent with durable polymer for coronary revascularisation (LEADERS): a randomised non-inferiority trial , 2008, The Lancet.

[62]  A. Kastrati,et al.  A polymer-free dual drug-eluting stent in patients with coronary artery disease: a randomized trial vs. polymer-based drug-eluting stents. , 2008, European heart journal.

[63]  A. Colombo,et al.  Bifurcation stenting: current strategies and new devices , 2008, Heart.

[64]  K. Robinson,et al.  Novel bioabsorbable salicylate‐based polymer as a drug‐eluting stent coating , 2008, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.

[65]  P. Stella,et al.  One year results of a new in situ length-adjustable stent platform with a biodegradable biolimus A9 eluting polymer: results of the CUSTOM-II trial. , 2008, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.

[66]  M. Niemelä,et al.  Safety in simple versus complex stenting of coronary artery bifurcation lesions. The nordic bifurcation study 14-month follow-up results. , 2008, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.

[67]  K. Niemelä.  Biodegradable coating for drug-eluting stents--more than a facelift? , 2008, European heart journal.

[68]  A. Wieczorek,et al.  Randomized trial of three rapamycin-eluting stents with different coating strategies for the reduction of coronary restenosis. , 2008, European heart journal.

[69]  R. Virmani,et al.  Endothelial cell recovery between comparator polymer-based drug-eluting stents. , 2008, Journal of the American College of Cardiology.

[70]  M. Böhm,et al.  Two year follow-up after treatment of coronary in-stent restenosis with a paclitaxel-coated balloon catheter , 2008, Clinical Research in Cardiology.

[71]  W. Wijns,et al.  Differential effects of drug-eluting stents on local endothelium-dependent coronary vasomotion. , 2008, Journal of the American College of Cardiology.

[72]  P. Fitzgerald,et al.  EXCELLA First-in-Man (FIM) study: safety and efficacy of novolimus-eluting stent in de novo coronary lesions. , 2008, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.

[73]  S. Jain,et al.  Biodegradable-polymer-based, sirolimus-eluting Supralimus stent: 6-month angiographic and 30-month clinical follow-up results from the series I prospective study. , 2008, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.

[74]  M. Böhm,et al.  Hotline update of clinical trials and registries presented at the German Cardiac Society meeting 2008 , 2008, Clinical Research in Cardiology.

[75]  Mitchell W. Krucoff,et al.  A novel bioresorbable polymer paclitaxel-eluting stent for the treatment of single and multivessel coronary disease: primary results of the COSTAR (Cobalt Chromium Stent With Antiproliferative for Restenosis) II study. , 2008, Journal of the American College of Cardiology.

[76]  P. Stella,et al.  Safety and efficacy of drug‐eluting balloons in percutaneous treatment of bifurcation lesions the DEBIUT (drug‐eluting balloon in bifurcaton utrecht) registry , 2008, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.

[77]  Patrick W Serruys,et al.  A bioabsorbable everolimus-eluting coronary stent system for patients with single de-novo coronary artery lesions (ABSORB): a prospective open-label trial , 2008, The Lancet.

[78]  P. Serruys,et al.  Tryton I, First-In-Man (FIM) study: six month clinical and angiographic outcome, analysis with new quantitative coronary angiography dedicated for bifurcation lesions. , 2008, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.

[79]  B. Beleslin,et al.  First clinical comparison of Nobori -Biolimus A9 eluting stents with Cypher- Sirolimus eluting stents: Nobori Core nine months angiographic and one year clinical outcomes. , 2008, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.

[80]  Franz Schwarz,et al.  Comparison of a polymer‐free rapamycin‐eluting stent (YUKON) with a polymer‐based paclitaxel‐eluting stent (TAXUS) in real‐world coronary artery lesions , 2008, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.

[81]  J. Granada,et al.  vProtect luminal shield system. , 2007, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.

[82]  P. Serruys,et al.  Accelerated vascular repair following percutaneous coronary intervention by capture of endothelial progenitor cells promotes regression of neointimal growth at long term follow-up: final results of the Healing II trial using an endothelial progenitor cell capturing stent (Genous R stent). , 2007, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.

[83]  P. Serruys,et al.  Comparison of in vivo acute stent recoil between the bioabsorbable everolimus-eluting coronary stent and the everolimus-eluting cobalt chromium coronary stent: insights from the ABSORB and SPIRIT trials. , 2007 .

[84]  J. Ormiston,et al.  The AST petal dedicated bifurcation stent: First‐in‐human experience , 2007, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.

[85]  Michael Joner,et al.  Vascular Responses to Drug Eluting Stents: Importance of Delayed Healing , 2007, Arteriosclerosis, thrombosis, and vascular biology.

[86]  Brett Trauthen,et al.  Six-month clinical and angiographic results of a dedicated drug-eluting stent for the treatment of coronary bifurcation narrowings. , 2007, The American journal of cardiology.

[87]  Raimund Erbel,et al.  Temporary scaffolding of coronary arteries with bioabsorbable magnesium stents: a prospective, non-randomised multicentre trial , 2007, The Lancet.

[88]  R. Whitbourn,et al.  The next-generation Endeavor Resolute stent: 4-month clinical and angiographic results from the Endeavor Resolute first-in-man trial. , 2007, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.

[89]  P. Serruys,et al.  Circulating endothelial progenitor cells predict angiographic and intravascular ultrasound outcome following percutaneous coronary interventions in the HEALING-II trial: evaluation of an endothelial progenitor cell capturing stent. , 2007, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.

[90]  J. Wilcox,et al.  The next generation Endeavor Resolute Stent: role of the BioLinx Polymer System. , 2007, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.

[91]  P. Serruys,et al.  The European cobalt STent with Antiproliferative for Restenosis trial (EuroSTAR): 12 month results. , 2007, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.

[92]  D. Baim,et al.  Polymer-based, paclitaxel-eluting TAXUS Liberté stent in de novo lesions: the pivotal TAXUS ATLAS trial. , 2007, Journal of the American College of Cardiology.

[93]  Johan Lindbäck,et al.  Long-term outcomes with drug-eluting stents versus bare-metal stents in Sweden. , 2007, The New England journal of medicine.

[94]  A. Lansky,et al.  Cobalt chromium stent with antiproliferative for restenosis trial in India (COSTAR I). , 2007, Indian heart journal.

[95]  K. Node,et al.  Mobilization of CD34-Positive Bone Marrow–Derived Cells After Coronary Stent Implantation: Impact on Restenosis , 2007, Circulation.

[96]  K. Robinson,et al.  Scanning electron microscopic analysis of defects in polymer coatings of three commercially available stents: comparison of BiodivYsio, Taxus and Cypher stents. , 2007, The Journal of invasive cardiology.

[97]  J. E. Sousa,et al.  Bifurcated stents: giving to Caesar what is Caesar's. , 2007, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.

[98]  John A Ormiston,et al.  First‐in‐human implantation of a fully bioabsorbable drug‐eluting stent: The BVS poly‐L‐lactic acid everolimus‐eluting coronary stent , 2007, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.

[99]  M. Briel,et al.  Mortality in randomized controlled trials comparing drug-eluting vs. bare metal stents in coronary artery disease: a meta-analysis. , 2006, European heart journal.

[100]  M. Böhm,et al.  Two year follow-up after treatment of coronary in-stent restenosis with a paclitaxel-coated balloon catheter. , 2006, Clinical research in cardiology : official journal of the German Cardiac Society.

[101]  P. Serruys,et al.  Biodegradable-polymer-based, paclitaxel-eluting Infinnium stent: 9-Month clinical and angiographic follow-up results from the SIMPLE II prospective multi-centre registry study. , 2006, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.

[102]  P. Serruys,et al.  A randomised comparison of an everolimus-eluting coronary stent with a paclitaxel-eluting coronary stent:the SPIRIT II trial. , 2006, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.

[103]  Karl-Heinz Waldmann,et al.  Safety and efficacy of bioabsorbable magnesium alloy stents in porcine coronary arteries , 2006, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.

[104]  Michael Joner,et al.  Pathology of drug-eluting stents in humans: delayed healing and late thrombotic risk. , 2006, Journal of the American College of Cardiology.

[105]  J. Oldenburg,et al.  Hemophilia A Patients with Undetectable Mutations: Current Knowledge and Future Directions* , 2006, Transfusion Medicine and Hemotherapy.

[106]  Taisuke Mori,et al.  Retention of paclitaxel in cancer cells for 1 week in vivo and in vitro , 2006, Cancer Chemotherapy and Pharmacology.

[107]  A. Yeung,et al.  Long-Term Histopathologic and IVUS Evaluations of a Novel Coiled Sheet Stent in Porcine Carotid Arteries , 2006, CardioVascular and Interventional Radiology.

[108]  A. Yeung,et al.  Acute and long‐term outcomes of the novel side access (SLK‐View™) stent for bifurcation coronary lesions: A multicenter nonrandomized feasibility study , 2006, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.

[109]  Ron Waksman,et al.  Biodegradable stents: they do their job and disappear. , 2006, The Journal of invasive cardiology.

[110]  Jörg Hausleiter,et al.  Randomized Trial of a Nonpolymer-Based Rapamycin-Eluting Stent Versus a Polymer-Based Paclitaxel-Eluting Stent for the Reduction of Late Lumen Loss , 2006, Circulation.

[111]  P. Serruys,et al.  Serial assessment of tissue growth inside and outside the stent after implantation of drug-eluting stent in clinical trials. - Does delayed neointimal growth exist? , 2005, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.

[112]  W. J. van der Giessen,et al.  The Frontier stent registry: safety and feasibility of a novel dedicated stent for the treatment of bifurcation coronary artery lesions. , 2005, Journal of the American College of Cardiology.

[113]  A. Kastrati,et al.  Prevention of restenosis by a novel drug-eluting stent system with a dose-adjustable, polymer-free, on-site stent coating. , 2005, European heart journal.

[114]  Frank Litvack,et al.  The effect of variable dose and release kinetics on neointimal hyperplasia using a novel paclitaxel-eluting stent platform: the Paclitaxel In-Stent Controlled Elution Study (PISCES). , 2005, Journal of the American College of Cardiology.

[115]  R. Virmani,et al.  Differential Response of Delayed Healing and Persistent Inflammation at Sites of Overlapping Sirolimus- or Paclitaxel-Eluting Stents , 2005, Circulation.

[116]  A. Kastrati,et al.  Influence of stent surface topography on the outcomes of patients undergoing coronary stenting: A randomized double‐blind controlled trial , 2005, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.

[117]  I. Iakovou,et al.  Treatment of bifurcation lesions with two stents: one year angiographic and clinical follow up of crush versus T stenting , 2005, Heart.

[118]  F. Eberli,et al.  Randomized Comparison of a Titanium-Nitride-Oxide–Coated Stent With a Stainless Steel Stent for Coronary Revascularization: The TiNOX Trial , 2005, Circulation.

[119]  P. Serruys,et al.  Endothelial progenitor cell capture by stents coated with antibody against CD34: the HEALING-FIM (Healthy Endothelial Accelerated Lining Inhibits Neointimal Growth-First In Man) Registry. , 2005, Journal of the American College of Cardiology.

[120]  W. D. de Jong,et al.  Tissue response to partially in vitro predegraded poly-L-lactide implants. , 2005, Biomaterials.

[121]  Jan J Piek,et al.  A randomized comparison of a durable polymer Everolimus-eluting stent with a bare metal coronary stent: The SPIRIT first trial. , 2005, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.

[122]  G. Stone,et al.  Relationship between angiographic late loss and target lesion revascularization after coronary stent implantation: analysis from the TAXUS-IV trial. , 2005, Journal of the American College of Cardiology.

[123]  S. Milz,et al.  Inhibition of Neointima Formation by a Novel Drug-Eluting Stent System That Allows for Dose-Adjustable, Multiple, and On-Site Stent Coating , 2005, Arteriosclerosis, thrombosis, and vascular biology.

[124]  Matthias Stuber,et al.  Artifact-Free Coronary Magnetic Resonance Angiography and Coronary Vessel Wall Imaging in the Presence of a New, Metallic, Coronary Magnetic Resonance Imaging Stent , 2005, Circulation.

[125]  M. Pan,et al.  Rapamycin-eluting stents for the treatment of bifurcated coronary lesions: a randomized comparison of a simple versus complex strategy. , 2004, American heart journal.

[126]  M. Böhm,et al.  Paclitaxel Balloon Coating, a Novel Method for Prevention and Therapy of Restenosis , 2004, Circulation.

[127]  N. Krott,et al.  Long-term assessment of a novel biodegradable paclitaxel-eluting coronary polylactide stent. , 2004, European heart journal.

[128]  Naofumi Hayabuchi,et al.  Conformity of carotid stents with vascular anatomy: evaluation in carotid models. , 2004, AJNR. American journal of neuroradiology.

[129]  H. Morita,et al.  Evaluation of the usefulness of recording the ECG in the 3rd intercostal space and prevalence of Brugada-type ECG in accordance with recently established electrocardiographic criteria. , 2004, Circulation journal : official journal of the Japanese Circulation Society.

[130]  Antonio Colombo,et al.  Randomized Study to Evaluate Sirolimus-Eluting Stents Implanted at Coronary Bifurcation Lesions , 2004, Circulation.

[131]  H. Uehata,et al.  FRS-177 Four-year Follow-up of the Biodegradable Stent (IGAKI-TAMAI Stent)(Percutaneous Coronary Intervention (IHD) : FRS21)(Featured Research Session (English)) , 2004 .

[132]  G. Stone,et al.  A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease. , 2004, The New England journal of medicine.

[133]  Renu Virmani,et al.  Pathological Mechanisms of Fatal Late Coronary Stent Thrombosis in Humans , 2003, Circulation.

[134]  A Haverich,et al.  Left main coronary artery fistula exiting into the right atrium , 2003, Heart.

[135]  J. Rieber,et al.  Stent design‐related coronary artery remodeling and patterns of neointima formation following self‐expanding and balloon‐expandable stent implantation , 2002, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.

[136]  A. Kastrati,et al.  Intracoronary Stenting and Angiographic Results: Strut Thickness Effect on Restenosis Outcome (ISAR-STEREO) Trial , 2001, Circulation.

[137]  AlbertSchömig,et al.  Intracoronary Stenting and Angiographic Results , 2001 .

[138]  H. Uehata,et al.  Initial and 6-month results of biodegradable poly-l-lactic acid coronary stents in humans. , 2000, Circulation.

[139]  A. Baumbach,et al.  Local paclitaxel delivery for the prevention of restenosis: biological effects and efficacy in vivo. , 2000, Journal of the American College of Cardiology.

[140]  R. Virmani,et al.  Lessons from sudden coronary death: a comprehensive morphological classification scheme for atherosclerotic lesions. , 2000, Arteriosclerosis, thrombosis, and vascular biology.

[141]  K. Kodama,et al.  Angiographic and clinical outcome of a new self‐expanding intracoronary stent (RADIUS): Results from multicenter experience in Japan , 2000, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.

[142]  J. Tobis,et al.  Bifurcation lesions: two stents versus one stent--immediate and follow-up results. , 2000, Journal of the American College of Cardiology.

[143]  H Shimokawa,et al.  Intramural delivery of a specific tyrosine kinase inhibitor with biodegradable stent suppresses the restenotic changes of the coronary artery in pigs in vivo. , 1998, Journal of the American College of Cardiology.

[144]  S. Nattel,et al.  Probucol and multivitamins in the prevention of restenosis after coronary angioplasty. Multivitamins and Probucol Study Group. , 1997, The New England journal of medicine.

[145]  A. Küttner,et al.  Paclitaxel inhibits arterial smooth muscle cell proliferation and migration in vitro and in vivo using local drug delivery. , 1997, Circulation.

[146]  W S Pietrzak,et al.  Bioabsorbable Polymer Science for the Practicing Surgeon , 1997, The Journal of craniofacial surgery.

[147]  E. Topol,et al.  Marked inflammatory sequelae to implantation of biodegradable and nonbiodegradable polymers in porcine coronary arteries. , 1996, Circulation.

[148]  J. Sixma,et al.  Thrombogenicity of the human arterial wall after interventional thermal injury. , 1996, Journal of vascular research.

[149]  M. Leon,et al.  Dose-dependent smooth muscle cell proliferation induced by thermal injury with pulsed infrared lasers , 1992, 1992 14th Annual International Conference of the IEEE Engineering in Medicine and Biology Society.

[150]  F Joffre,et al.  Intravascular stents to prevent occlusion and restenosis after transluminal angioplasty. , 1987, The New England journal of medicine.

[151]  R. Whitbourn,et al.  Long-term clinical outcomes with the next-generation Resolute Stent System: a report of the two-year follow-up from the RESOLUTE clinical trial. , 2010, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.

[152]  R. Virmani,et al.  Histopathologic evaluation of nitinol self-expanding stents in an animal model of advanced atherosclerotic lesions. , 2010, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.

[153]  P. Serruys,et al.  An optical coherence tomography study of a biodegradable vs. durable polymer-coated limus-eluting stent: a LEADERS trial sub-study. , 2010, European heart journal.

[154]  P. Serruys,et al.  Assessment of the absorption process following bioabsorbable everolimus-eluting stent implantation: temporal changes in strain values and tissue composition using intravascular ultrasound radiofrequency data analysis. A substudy of the ABSORB clinical trial. , 2009, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.

[155]  E. Ribeiro,et al.  Randomized evaluation of two drug-eluting stents with identical metallic platform and biodegradable polymer but different agents (paclitaxel or sirolimus) compared against bare stents: 1-year results of the PAINT trial. , 2009, Catheterization and cardiovascular interventions.

[156]  Eric Ashby,et al.  Cause for concern , 1983, Nature.